A detailed history of Black Rock Inc. transactions in Prelude Therapeutics Inc stock. As of the latest transaction made, Black Rock Inc. holds 1,068,916 shares of PRLD stock, worth $1.02 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,068,916
Previous 1,097,474 2.6%
Holding current value
$1.02 Million
Previous $5.2 Million 21.72%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

SELL
$3.32 - $5.63 $94,812 - $160,781
-28,558 Reduced 2.6%
1,068,916 $4.07 Million
Q1 2024

May 10, 2024

BUY
$2.68 - $4.84 $5,051 - $9,123
1,885 Added 0.17%
1,097,474 $5.2 Million
Q4 2023

Feb 13, 2024

BUY
$1.69 - $4.37 $45,891 - $118,667
27,155 Added 2.54%
1,095,589 $4.68 Million
Q3 2023

Nov 13, 2023

BUY
$2.74 - $4.79 $573,517 - $1 Million
209,313 Added 24.36%
1,068,434 $3.3 Million
Q2 2023

Aug 11, 2023

BUY
$4.45 - $8.12 $1.94 Million - $3.54 Million
436,093 Added 103.09%
859,121 $3.87 Million
Q1 2023

May 12, 2023

BUY
$4.58 - $7.34 $134,995 - $216,346
29,475 Added 7.49%
423,028 $2.41 Million
Q4 2022

Feb 13, 2023

SELL
$4.61 - $8.5 $302,328 - $557,438
-65,581 Reduced 14.28%
393,553 $2.38 Million
Q3 2022

Nov 14, 2022

SELL
$5.0 - $8.82 $351,505 - $620,054
-70,301 Reduced 13.28%
459,134 $3.03 Million
Q2 2022

Aug 12, 2022

SELL
$4.0 - $7.55 $2.09 Million - $3.95 Million
-522,525 Reduced 49.67%
529,435 $2.76 Million
Q1 2022

May 12, 2022

BUY
$6.9 - $13.22 $1.07 Million - $2.06 Million
155,456 Added 17.34%
1,051,960 $7.26 Million
Q4 2021

Feb 10, 2022

BUY
$11.89 - $31.74 $2.03 Million - $5.41 Million
170,542 Added 23.49%
896,504 $11.2 Million
Q3 2021

Nov 09, 2021

BUY
$25.78 - $38.65 $596,033 - $893,588
23,120 Added 3.29%
725,962 $22.7 Million
Q2 2021

Aug 11, 2021

BUY
$28.63 - $44.3 $20.1 Million - $31.1 Million
702,842 New
702,842 $20.1 Million

Others Institutions Holding PRLD

About Prelude Therapeutics Inc


  • Ticker PRLD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 36,369,200
  • Market Cap $34.6M
  • Description
  • Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT543 that is in Phase 1 clinical trials in select solid tumors and myeloid malignancies; and PRT811, which is in Phase 1 clinical trials in solid ...
More about PRLD
Track This Portfolio

Track Black Rock Inc. Portfolio

Follow Black Rock Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

News

Stay updated on Black Rock Inc. with notifications on news.